Frontpage Hero

Because we care, we need to act

Sobi Scientific Innovation Awards

Innovative researchers win inaugural Sobi awards

Sobi has announced the winners of the inaugural Sobi Scientific Innovation Awards: Assistant Professor Víctor Jiménez-Yuste from Madrid, Spain and Dr Davide Matino from Hamilton, Canada. Their work has been recognised for elevating understanding of haemophilia and raising the standard of care, helping patients live a life beyond haemophilia.
Sobi 2018 Annual and Sustainability Report

Sobi 2018 Annual and Sustainability Report

"2018 was a year of transformation for Sobi,” says Guido Oelkers, CEO and President. “Our substantial progress in Haemophilia, acquisitions in Immunology and sales growth in Specialty Care mean that the company is essentially, on a pro-forma basis, two-and-a-half times the size it was at the end of 2016. But it is important to understand that we see this as an important stepping stone. In the Annual and Sustainability Report, we outline how the strong growth we delivered throughout 2018 is fuelling our vision of becoming global leaders in providing innovative treatments that transform life for people with rare diseases".

Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces today that revenue and EBITA for the full year 2019 were higher than previous estimates. Full-year revenue was approximately SEK 14,150 –14,250 M and EBITA approximately SEK 6,200 – 6,300 M, excluding...

01/16/2020 - 19:00

Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation[1] (ODD) by the US Food and Drug Administration (FDA) for avatrombopag for the potential treament of Chemotherapy-Induced...

12/21/2019 - 08:00

SobiTM and Sanofi today announced that the first patient has been dosed in the phase 3, open-label, interventional study of BIVV001 (rFVIIIFc-VWF-XTEN), in patients with severe haemophilia A (XTEND-1 study; NCT04161495). Sobi and Sanofi are development partners for...

12/11/2019 - 08:00

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented additional analyses from the phase 3 study – core and extension phase - with avatrombopag (AVA) for the treatment of immune thrombocytopenia (ITP), at the 61st...

12/09/2019 - 07:05
Contact us

Sobi Head Office
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden